Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 1
1975 1
1976 4
1977 1
1978 1
1979 1
1980 2
1981 1
1983 1
1984 2
1985 2
1986 3
1987 6
1988 4
1989 2
1990 7
1991 5
1992 3
1993 2
1994 2
1995 7
1996 3
1997 8
1998 3
1999 10
2000 5
2001 9
2002 6
2003 12
2004 11
2005 5
2006 9
2007 7
2008 5
2009 7
2010 8
2011 7
2012 4
2013 4
2014 10
2015 7
2016 11
2017 7
2018 9
2019 6
2020 10
2021 4
2022 12
2023 12
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

259 results

Results by year

Filters applied: . Clear all
Page 1
Physical fitness in Indian women with epilepsy on anti-seizure medications and its association with reproductive status, quality of life and stigma: A cross-sectional study.
Pattnaik SS, Sarangi SC, Mahey R, Tripathi M. Pattnaik SS, et al. Epilepsy Behav. 2024 Jul;156:109823. doi: 10.1016/j.yebeh.2024.109823. Epub 2024 May 4. Epilepsy Behav. 2024. PMID: 38704986
Subjects were interviewed for menstrual abnormalities [menstrual disturbance or Polycystic Ovary Syndrome (PCOS)/hirsutism]. Validated questionnaires were used for assessment of, QOL (QOLIE-10) and Stigma in epilepsy (Epilepsy Stigma Scale). ...No significant difference in …
Subjects were interviewed for menstrual abnormalities [menstrual disturbance or Polycystic Ovary Syndrome (PCOS)/hirsutism]. Validate …
Improvement in clinical features of hypercortisolism during osilodrostat treatment: findings from the Phase III LINC 3 trial in Cushing's disease.
Pivonello R, Fleseriu M, Newell-Price J, Shimatsu A, Feelders RA, Kadioglu P, Tabarin A, Brue TC, Geer EB, Piacentini A, Pedroncelli AM, Biller BMK. Pivonello R, et al. J Endocrinol Invest. 2024 May 2. doi: 10.1007/s40618-024-02359-6. Online ahead of print. J Endocrinol Invest. 2024. PMID: 38696122
CONCLUSIONS: Improvements in clinical signs and additional specific manifestations of hypercortisolism associated with Cushing's disease occurred alongside decreases in mUFC. Trial registration NCT02180217 (first posted July 2014)....
CONCLUSIONS: Improvements in clinical signs and additional specific manifestations of hypercortisolism associated with Cushing's dise …
Adolescents diagnosed with polycystic ovary syndrome under the Rotterdam criteria but not meeting the diagnosis under the updated guideline.
Kim JJ, Hwang KR, Lee D, Kim S, Choi YM. Kim JJ, et al. Hum Reprod. 2024 May 2;39(5):1072-1077. doi: 10.1093/humrep/deae042. Hum Reprod. 2024. PMID: 38514450
WHAT IS KNOWN ALREADY: The international evidence-based PCOS guideline recommended that ultrasound should not be used for the diagnosis of PCOS in girls with a gynecological age of <8 years. Thus far, few studies have evaluated the clinical characteristics of the …
WHAT IS KNOWN ALREADY: The international evidence-based PCOS guideline recommended that ultrasound should not be used for the diagnosis of P …
Testosterone therapy in females is not associated with increased cardiovascular or breast cancer risk: a claims database analysis.
Agrawal P, Singh SM, Hsueh J, Grutman A, An C, Able C, Choi U, Kohn J, Clifton M, Kohn TP. Agrawal P, et al. J Sex Med. 2024 Apr 30;21(5):414-419. doi: 10.1093/jsxmed/qdae032. J Sex Med. 2024. PMID: 38459625
Females aged 56 years with TTh had a similar risk of MACE (RR, 0.84; 95% CI, 0.64-1.10), DVT (RR, 0.82; 95% CI, 0.50-1.36), and PE (RR, 0.52; 95% CI, 0.26-1.05) and a significantly lower risk of malignant breast neoplasm (RR, 0.51; 95% CI, 0.38-0.68). Risk of hirsutism was …
Females aged 56 years with TTh had a similar risk of MACE (RR, 0.84; 95% CI, 0.64-1.10), DVT (RR, 0.82; 95% CI, 0.50-1.36), and PE (RR, 0.52 …
Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines.
Fitz V, Graca S, Mahalingaiah S, Liu J, Lai L, Butt A, Armour M, Rao V, Naidoo D, Maunder A, Yang G, Vaddiparthi V, Witchel SF, Pena A, Spritzer PM, Li R, Tay C, Mousa A, Teede H, Ee C. Fitz V, et al. J Clin Endocrinol Metab. 2024 May 17;109(6):1630-1655. doi: 10.1210/clinem/dgad762. J Clin Endocrinol Metab. 2024. PMID: 38163998 Free PMC article.
DATA EXTRACTION: Data were extracted for hormonal, metabolic, lipids, psychological, anthropometric, reproductive outcomes, and adverse effects by 1 reviewer, independently verified by a second. ...Evidence suggests benefits for myo-inositol or D-chiro-inositol (DCI) for s …
DATA EXTRACTION: Data were extracted for hormonal, metabolic, lipids, psychological, anthropometric, reproductive outcomes, and adver …
The role of berberine in polycystic ovary syndrome - a summary of knowledge.
Jurgiel J, Graniak A, Opyd P, Zawodny T, Lis M. Jurgiel J, et al. Ginekol Pol. 2024;95(4):276-284. doi: 10.5603/gpl.95138. Epub 2023 Dec 18. Ginekol Pol. 2024. PMID: 38108460 Free article. Review.
Previous studies have demonstrated that berberine can improve hormonal imbalances by reducing testosterone and FAI, increasing SHBG, and mitigating the clinical symptoms of androgen excess, including hirsutism and acne. Moreover, berberine enhances the therapeutic e …
Previous studies have demonstrated that berberine can improve hormonal imbalances by reducing testosterone and FAI, increasing SHBG, and mit …
Effect of Berberine Phytosome on reproductive, dermatologic, and metabolic characteristics in women with polycystic ovary syndrome: a controlled, randomized, multi-centric, open-label clinical trial.
Di Pierro F, Sultana R, Eusaph AZ, Abrar S, Bugti M, Afridi F, Farooq U, Iqtadar S, Ghauri F, Makhduma S, Nourin S, Kanwal A, Bano A, Bugti AA, Mureed S, Ghazal A, Irshad R, Recchia M, Bertuccioli A, Putignano P, Riva A, Guasti L, Zerbinati N, Khan A. Di Pierro F, et al. Front Pharmacol. 2023 Nov 21;14:1269605. doi: 10.3389/fphar.2023.1269605. eCollection 2023. Front Pharmacol. 2023. PMID: 38074133 Free PMC article.
It has also been reported to reduce signs and symptoms of polycystic ovary syndrome (PCOS). Objective: To explore, through a multi-centric, randomized, controlled and prospective study, the possible role played by a form berberine that is more easily absorbed (Berberine Ph …
It has also been reported to reduce signs and symptoms of polycystic ovary syndrome (PCOS). Objective: To explore, through a multi-centric, …
SPIOMET4HEALTH-efficacy, tolerability and safety of lifestyle intervention plus a fixed dose combination of spironolactone, pioglitazone and metformin (SPIOMET) for adolescent girls and young women with polycystic ovary syndrome: study protocol for a multicentre, randomised, double-blind, placebo-controlled, four-arm, parallel-group, phase II clinical trial.
Garcia-Beltran C, Malpique R, Andersen MS, Bas F, Bassols J, Darendeliler F, Díaz M, Dieris B, Fanelli F, Fröhlich-Reiterer E, Gambineri A, Glintborg D, López-Bermejo A, Mann C, Marin S, Obermayer-Pietsch B, Ødegård R, Ravn P, Reinehr T, Renzulli M, Salvador C, Singer V, Vanky E, Torres JV, Yildiz M, de Zegher F, Ibáñez L. Garcia-Beltran C, et al. Trials. 2023 Sep 15;24(1):589. doi: 10.1186/s13063-023-07593-6. Trials. 2023. PMID: 37715279 Free PMC article.
METHODS: In this multicentre, randomised, double-blind, placebo-controlled, four-arm, parallel-group, phase II clinical trial, AYAs with PCOS will be recruited from 7 clinical centres across Europe. ...TRIAL REGISTRATION: EudraCT 2021-003177-58. …
METHODS: In this multicentre, randomised, double-blind, placebo-controlled, four-arm, parallel-group, phase II clinical tri
Different kinds of oral contraceptive pills in polycystic ovary syndrome: a systematic review and meta-analysis.
Forslund M, Melin J, Alesi S, Piltonen T, Romualdi D, Tay CT, Witchel S, Pena A, Mousa A, Teede H. Forslund M, et al. Eur J Endocrinol. 2023 Jul 20;189(1):S1-S16. doi: 10.1093/ejendo/lvad082. Eur J Endocrinol. 2023. PMID: 37440702
METHODS: MEDLINE, EMBASE, All EBM, CINAHL, and PsycINFO was searched on July, 8, 2022, for studies including women with PCOS, comparing 2 different COCPs in randomized controlled trials. RESULTS: A total of 1660 studies were identified, and 19 randomized controlled …
METHODS: MEDLINE, EMBASE, All EBM, CINAHL, and PsycINFO was searched on July, 8, 2022, for studies including women with PCOS, comparing 2 di …
Evaluation of the efficacy of an antioxidant combination for the modulation of metabolic, endocrine, and clinical parameters in patients with polycystic ovary syndrome.
Pingarrón Santofímia C, Poyo Torcal S, López Verdú H, Henríquez Linares A, Calvente Aguilar V, Terol Sánchez P, Martínez García MS, Lafuente González P. Pingarrón Santofímia C, et al. Gynecol Endocrinol. 2023 Jun 19;39(1):2227277. doi: 10.1080/09513590.2023.2227277. Gynecol Endocrinol. 2023. PMID: 37356455 Free article. Clinical Trial.
General recommendation of healthy diet and regular exercise was given to all patients. Metabolic, endocrine, clinical, and quality of life parameters were recorded at baseline and after 6 months of therapy. ...
General recommendation of healthy diet and regular exercise was given to all patients. Metabolic, endocrine, clinical, and qua
259 results